DURHAM, N.C., March 17, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that Doug Plessinger, vice president of clinical and medical affairs, is scheduled to present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum at the New York Academy of Sciences in New York City. Mr. Plessinger's presentation will include an update on Argos's clinical development program for AGS-003, the company's personalized immunotherapy currently in a pivotal phase 3 clinical trial for the treatment of metastatic renal cell carcinoma.
| Event: | 2nd Annual Sachs Cancer Bio Partnering & Investment Forum |
| Date: | Wednesday, March 19, 2014 |
| Time: | 2:00 p.m. ET |
Mr. Plessinger will also participate in a panel discussion during the meeting entitled Immunotherapies & Cancer Vaccines. The panel discussion will begin at 11:45 a.m. ET on March 19, 2014.
About Argos Therapeutics
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos´ most advanced product candidate, AGS-003, is in a pivotal Phase 3 trial for the treatment of mRCC, and the company plans to have data from its Phase 2b trial of AGS-004 for the treatment of HIV in mid- 2014. For more information about Argos Therapeutics, visit www.argostherapeutics.com.